Partner, Greg Williams, advised the funders on a £3.8m investment round into the Cardiff-based healthtech start-up which develops bioelectronic technology that mimics nerve centres to control a range of autonomic or rhythmical processes in the human body.
The funding will be used to commercialise Ceryx’s cardiology technology and start the first-in-human clinical study of its cardiac rhythm management device, Cysoni later this year.
“It’s been a pleasure to advise Development Bank of Wales, and the Business Growth Fund on this investment into such an exciting project for Ceryx Medical. The transaction demonstrates the funding readily available in the life science sector for innovative, and potentially lifesaving technology.”
You can read more about this deal in this Insider Media article.
Hugh James has a strong track record in advising funders and the life sciences sector. It recently supported Creo Medical Group PLC on its latest expansion.